There are currently 2707 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
NCT05467683
Recruiting
Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Massachusetts Cancer Research Center, Boston, Massachusetts
Conditions: cGVHD
Register for Updates
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT06096116
Recruiting
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acquired Antithrombin Deficiency
Register for Updates
Novel Digital Application for Patients With Acute Leukemia
NCT06472128
Recruiting
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Register for Updates
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334
Recruiting
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Dana-Farber Cancer Institute ( Site 4047), Boston, Massachusetts
Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Register for Updates
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/18/2025
Locations: Boston Specialists, Boston, Massachusetts
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
Recruiting
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2025
Locations: Boston Clinical Trials Llc, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Improving Coronary Vascular Health in Women
NCT06843902
Recruiting
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health educati... Read More
Gender:
FEMALE
Ages:
Between 45 years and 75 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Register for Updates
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Obesity
Register for Updates